|
Table 1: Clinical characteristics. |
|||
|
Characteristic |
Non-complex (N = 794) n (%) |
Complex (N = 203) n (%) |
p |
|
Age (years) |
76.84 ± 13.26 |
65.31 ± 13.25 |
0.000* |
|
Gender |
|
|
0.002 |
|
Male |
423 (76.4) |
131 (23.6) |
|
|
Female |
371 (83.7) |
72 (16.3) |
|
|
Comorbidities |
|
|
|
|
Arterial hypertension |
642 (80.5) |
156 (19.5) |
0.120 |
|
Dyslipidemia |
370 (76.6) |
113 (23.4) |
0.013 |
|
Diabetes mellitus |
199 (79.0) |
53 (21.0) |
|
|
Hypothyroidism |
181 (80.0) |
45 (19.9) |
0.863 |
|
Obesity |
131 (84.5) |
24 (15.5) |
0.129 |
|
COPD |
108 (78.3) |
30 (21.7) |
0.709 |
|
Stroke |
63 (88.7) |
8 (11.3) |
0.217 |
|
TIA |
|
|
|
|
OSA |
21 (80.8) |
5 (19.2) |
0.559 |
|
Medication used |
|
|
|
|
Beta blockers |
343 (65.4) |
181 (34.6) |
0.000 |
|
ACE inhibitors |
135 (64.6) |
74 (35.4) |
0.000 |
|
ARBs |
379 (81.7) |
85 (18.3) |
0.112 |
|
MRAs |
81 (38.8) |
128 (61.2) |
0.000 |
|
Statins |
390 (72.2) |
149 (27.6) |
0.000‡ |
|
Furosemide |
189 (65.4) |
100 (34.6) |
0.000 |
|
Anticoagulants |
323 (72.9) |
120 (27.1) |
0.000 |
|
Antiplatelet agents |
44 (56.4) |
34 (43.6) |
0.000 |
|
COPD = chronic obstructive pulmonary disease, TIA = transient ischemic attack, OSA = obstructive sleep apnea, ACE = angiotensin-converting enzyme, ARBs = angiotensin receptor blockers, MRAs = mineralocorticoid receptor antagonists. *Student’s t-test. ‡ Fisher’s exact test. |
|||